Back

Roche’s giredestrant combination improves progression-free survival in advanced breast cancer

Verifying
  • Roche’s giredestrant combination improved progression-free survival in advanced breast cancer.
  • Phase III evERA data showed a significant benefit in ER-positive disease.
  • The results were published in The New England Journal of Medicine.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.